Pacific Biosciences of California (PACB) Getting Positive Media Coverage, Report Shows

Headlines about Pacific Biosciences of California (NASDAQ:PACB) have been trending positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pacific Biosciences of California earned a news impact score of 0.35 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 47.6862873369362 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Pacific Biosciences of California stock opened at $2.59 on Monday. The stock has a market capitalization of $338.50, a PE ratio of -2.91 and a beta of 1.54. Pacific Biosciences of California has a 1 year low of $2.21 and a 1 year high of $5.70. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.55 and a quick ratio of 2.74.

Pacific Biosciences of California (NASDAQ:PACB) last issued its quarterly earnings results on Thursday, February 1st. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.02. The company had revenue of $24.94 million for the quarter, compared to the consensus estimate of $21.89 million. Pacific Biosciences of California had a negative return on equity of 98.98% and a negative net margin of 98.63%. The firm’s revenue was down 3.1% compared to the same quarter last year. During the same period last year, the business posted ($0.21) earnings per share. sell-side analysts predict that Pacific Biosciences of California will post -0.63 EPS for the current year.

PACB has been the topic of several analyst reports. BidaskClub raised shares of Pacific Biosciences of California from a “strong sell” rating to a “sell” rating in a research report on Thursday, December 21st. Zacks Investment Research downgraded shares of Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $6.27.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes.

Insider Buying and Selling by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with's FREE daily email newsletter.

Leave a Reply